3α-Dihydroprogesterone (3α-DHP) is a neurosteroid derived from progesterone through the action of 3α-hydroxysteroid dehydrogenase (3α-HSD).
It exerts neuroprotective, anti-inflammatory, and antioxidant effects, modulating GABA_A receptor activity to provide anxiolytic, sedative, and anticonvulsant benefits. 3α-DHP also inhibits the release of follicle-stimulating hormone (FSH) while not affecting luteinizing hormone (LH), highlighting its unique regulatory roles.
Additionally, it demonstrates anti-proliferative and anti-metastatic properties in breast cancer cells, contrasting with the tumorigenic effects of 5α-dihydroprogesterone (5α-DHP).
3α-Dihydroprogesterone (3α-DHP) is a significant metabolite of progesterone produced by the enzymatic action of 3α-hydroxysteroid dehydrogenase (3α-HSD).
It exhibits potent neuroprotective and anti-inflammatory properties, as well as modulating GABA_A receptor activity, exerting anxiolytic, sedative, and anticonvulsant effects similar to allopregnanolone.
Additionally, 3α-DHP plays a role in breast cancer biology, demonstrating anti-proliferative and anti-metastatic effects in breast cancer cells, contrasting with the proliferative effects of its isomer, 5α-dihydroprogesterone (5α-DHP). [3.]
3α-DHP, as a neurosteroid, regulates neurotransmission, neurogenesis, synapse formation, myelination, cognition, mood, and neuronal survival.
It exerts its effects through modulation of GABA_A receptors and other signaling pathways, contributing to the maintenance of nervous system homeostasis. 3α-DHP’s modulation of GABA_A receptors enhances inhibitory neurotransmission and provides an anxiolytic effect.
3α-DHP has been shown to possess neuroprotective, antioxidant, and anti-inflammatory properties. It helps protect neurons from degeneration and reduces glial reactivity, which is crucial in preventing and managing neurodegenerative diseases.
It also interacts with membrane progesterone receptors (mPRs) and other signaling molecules to activate intracellular pathways that promote cell survival and neuroprotection.
3a-dihydroprogesterone has also been shown to specifically inhibit the release of follicle-stimulating hormone (FSH) from pituitary cells without affecting luteinizing hormone (LH). [4.]
Differential expression of progesterone metabolizing enzyme genes has been shown in human breast carcinoma.
Tumorous tissues show higher expression of 5α-reductase genes (5αR1 and 5αR2) and lower expression of 3α-hydroxysteroid oxidoreductase (3α-HSO2, 3α-HSO3) and 20α-hydroxysteroid oxidoreductase (20α-HSO) genes compared to normal tissues.
Ultimately, this affects the levels of the tumorigenic 5α-Dihydroprogesterone (5αP) vs. the anticancerous 3α-Dihydroprogesterone (3αHP) and 20α-Dihydroprogesterone (20αDHP).
Tumorous tissues produce higher levels of 5αP, a metabolite that promotes cell proliferation and detachment, thereby potentially encouraging tumor growth and metastasis.
Normal tissues produce higher levels of 3αHP and 20αDHP, which have anti-cancer effects by suppressing cell proliferation and detachment.
Elevated levels of 3α-DHP may indicate an imbalance in the hormonal cascade, particularly related to progesterone metabolism. This could disrupt normal hormonal function and potentially contribute to hormone-related symptoms or conditions.
As a metabolite of progesterone, 3α-DHP levels may provide insights into the regulation of progesterone and its effects on reproductive functions, such as the menstrual cycle and pregnancy.
3α-DHP is a neurosteroid that acts as a positive allosteric modulator of the GABA_A receptor. Its levels may influence neurological processes, including mood regulation, anxiety, and potentially memory and pain perception.
Testing for 3α-DHP could be relevant in the context of neurological disorders or conditions where GABA_A receptor modulation plays a role, such as anxiety disorders or epilepsy.
Testing for 3α-DHP levels could potentially provide insights into breast cancer risk assessment, particularly in postmenopausal women.
3a-Dihydroprogesterone is commonly tested in urine, often over 24 hours. Sample collection can be done from home. It is essential to consult with the ordering provider prior to sample collection, as certain medications, supplements or hormones (especially vaginally-applied hormones) can alter the test results.
3a-Dihydroprogesterone results should be interpreted in conjunction with other hormones and their metabolites to determine an individual’s overall hormone balance.
One lab reports optimal levels of 3a-dihydroprogesterone in urine as 0.67-2.03 μg/g Cr for premenopausal women in the luteal phase, or those women on progesterone replacement therapy. [7.]
Elevated levels of 3a-Dihydroprogesterone can be seen in altered steroid hormone metabolism, such as 21-hydroxylase deficiency, the main cause of congenital adrenal hyperplasia.
It may also indicate excessive progesterone production or supplementation in those individuals receiving progesterone replacement therapy.
Decreased levels of 3a-dihydroprogesterone indicate a low level of progesterone. Symptomatic individuals may consider progesterone replacement therapy.
To gain a comprehensive understanding of a patient's hormonal and neurosteroid profile, it is beneficial to test for related biomarkers alongside 3a-Dihydroprogesterone.
Progesterone is the precursor to 3a-Dihydroprogesterone, and its levels can provide valuable context for interpreting 3α-DHP results.
Measuring progesterone and its metabolites, such as allopregnanolone and pregnanolone, helps to elucidate the metabolic pathways and balance within the neurosteroid system.
Progesterone itself plays crucial roles in reproductive health, brain function, and neuroprotection.
By evaluating these metabolites, clinicians can better understand the overall hormonal environment, identify imbalances, and make more informed decisions regarding diagnosis and treatment.
This comprehensive hormonal profiling is particularly useful in cases involving mood disorders, menstrual irregularities, and neurodegenerative conditions.
It is essential to assess other hormonal biomarkers that interact with or influence the levels and effects of 3a-Dihydroprogesterone. Key hormones to consider include cortisol, estrogen, and testosterone.
Cortisol, the primary stress hormone, can significantly impact neurosteroid levels and has been linked to various psychiatric and neurological disorders.
Estrogen and testosterone, the primary sex hormones, influence neurosteroid synthesis and activity, playing roles in mood regulation, cognitive function, and overall brain health.
Evaluating these hormones alongside 3α-DHP provides a more comprehensive understanding of the patient's endocrine status, facilitating better diagnosis and personalized treatment strategies. This integrated approach helps to uncover complex hormonal interactions and their contributions to health and disease.
The FAQ section addresses common questions and concerns about 3a-Dihydroprogesterone, providing clear and concise answers for better understanding.
3a-Dihydroprogesterone (3α-DHP) is a metabolite of progesterone, a hormone that plays a key role in the reproductive system. It is produced in the body by the conversion of progesterone through the action of specific enzymes.
3a-Dihydroprogesterone is important because it has biological activity that can influence various physiological processes, including modulation of mood, neuroprotection, and regulation of the menstrual cycle.
Its levels can provide insights into hormonal balance and endocrine function.
3a-Dihydroprogesterone functions as a neurosteroid, impacting the central nervous system by modulating the activity of neurotransmitter receptors. It can have calming and anti-anxiety effects and may play a role in mood regulation.
It also contributes to reproductive health by participating in the menstrual cycle and pregnancy maintenance.
3a-Dihydroprogesterone levels can be measured through blood tests or urine tests. These tests are typically conducted in a laboratory where a sample is analyzed to determine the concentration of 3α-DHP in the body.
Normal levels of 3a-Dihydroprogesterone can vary based on factors such as age, sex, menstrual cycle phase, and overall health.
Reference ranges are provided by the testing laboratory and should be interpreted by a healthcare provider in the context of individual health circumstances.
Elevated levels of 3a-Dihydroprogesterone may be associated with certain health conditions, including adrenal hyperplasia, progesterone-secreting tumors, and some forms of congenital adrenal hyperplasia (CAH). Hormonal imbalances or certain medications can also lead to increased levels.
Low levels of 3a-Dihydroprogesterone may indicate issues such as adrenal insufficiency, hypothalamic-pituitary-adrenal (HPA) axis disorders, or insufficient production of progesterone. Chronic stress and certain health conditions can also contribute to reduced levels.
Symptoms of abnormal 3a-Dihydroprogesterone levels depend on whether levels are elevated or decreased. High levels may lead to symptoms of hormone imbalance such as menstrual irregularities, hirsutism (excessive hair growth), and mood changes.
Low levels may cause symptoms related to progesterone deficiency, such as menstrual cycle irregularities, fatigue, and anxiety.
Treatment for abnormal levels of 3a-Dihydroprogesterone depends on the underlying cause. Hormonal therapy may be used to balance hormone levels, and specific treatments for conditions like adrenal hyperplasia or adrenal insufficiency might be necessary.
It is important to consult with a healthcare provider for a proper diagnosis and treatment plan.
A doctor might order a 3a-Dihydroprogesterone test to investigate symptoms related to hormonal imbalances, assess adrenal gland function, or diagnose conditions such as congenital adrenal hyperplasia (CAH). It may also be part of a broader hormonal evaluation for issues related to mood disorders or reproductive health.
Yes, the 3a-Dihydroprogesterone test is safe. The most common risk associated with the test is slight discomfort or bruising at the site where blood is drawn. Urine tests are non-invasive and generally risk-free.
Click here to compare testing options and order tests for 3a-dihydroprogesterone.
[1.] Frye CA. Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions. Psychoneuroendocrinology. 2009 Dec;34 Suppl 1(Suppl 1):S143-61. doi: 10.1016/j.psyneuen.2009.07.005. PMID: 19656632; PMCID: PMC2898141.
[2.] Griffin LD, Mellon SH. Biosynthesis of the Neurosteroid 3α-Hydroxy-4-pregnen-20-one (3αHP), a Specific Inhibitor of FSH Release. Endocrinology. 2001;142(11):4617-4622. doi:https://doi.org/10.1210/endo.142.11.8477
[3.] Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer. 2004 Jun 22;4:27. doi: 10.1186/1471-2407-4-27. PMID: 15212687; PMCID: PMC459223.
[4.] Neurosteroids in Psychiatry - Pharmacology | Mechanisms of Action | Clinical Application. Psych Scene Hub. Published May 29, 2024. Accessed June 14, 2024. https://psychscenehub.com/psychinsights/neurosteroids-in-psychiatry/#google_vignette
[5.] Penning TM. Molecular Endocrinology of Hydroxysteroid Dehydrogenases*. Endocrine Reviews. 1997;18(3):281-305. doi:https://doi.org/10.1210/edrv.18.3.0302
[6.] Roglio I, Bianchi R, Gotti S, Scurati S, Giatti S, Pesaresi M, Caruso D, Panzica GC, Melcangi RC. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience. 2008 Aug 26;155(3):673-85. doi: 10.1016/j.neuroscience.2008.06.034. Epub 2008 Jun 19. PMID: 18625290.
[7.] Rupa Health. Sex Steroid Metabolites Sample Report.pdf. Google Docs. https://drive.google.com/file/d/1tN-AZcKD5N5QjRMhZRlgIJr61yw6OJU8/view